Power's 2025 Recap: What 10x Enrollment Growth Taught Us
In 2025, we achieved 10x growth in patients enrolled. Here's what actually moved the needle — and what we learned along the way.

In 2025, we achieved 10x growth in patients enrolled. Here's what actually moved the needle — and what we learned along the way.

More articles

What a compressed-timeline recruitment test revealed about execution at scale.

Your local call center knows exactly how every agent performed today. Your clinical trial sites? They're still filling out spreadsheets.

From brain circuit research at Stanford to building the operational infrastructure for precision psychiatry at scale.

How Joseph Palumbo went from a failed ALS program in 1996 to leading the first new ALS approval in two decades — and what patient selection had to do with it.

Same protocol. Same criteria. Different phrasing. Why your top sites convert 3x better — and how to find out what they're doing.

Most sponsors are flying blind between monthly reports while their sites are silently drowning. Here's how to catch problems in week 1 instead of week 10.

In 2025, we achieved 10x growth in patients enrolled. Here's what actually moved the needle — and what we learned along the way.

Strong start, steady month 2, then plateau. By month 3, enrollment rates drop 32% on average — and rarely recover. Here's why, and what to do about it.

Why patients who seem "engaged" disappear — and what site behaviors may be driving them away.

Great science means little without flawless execution. Here's what operational discipline looks like when it accelerates a regulatory timeline by nine to twelve months.

The AtaiBeckley merger reflects a bet that shorter treatment durations will improve patient access and payer acceptance.

72% of potential trial participants who call a site never make it to a screening visit. The gap between 'interested patient' and 'scheduled screening' is costing you enrollment.

What happens when a qualified patient is ready to engage... and nobody's available to respond? The case for rethinking your pre-screening model.

Why smart clin ops teams focus on practical AI wins instead of chasing shiny objects.